РЕЗЮМЕ. У всьому світі рак ендометрію є однією з найчастіше діагностованих злоякісних пухлин та значною причиною смерті жінок. Мета цього дослідження полягала в проведенні цитометричного аналізу плоїдності ДНК з візуалізацією, використовуючи передбачуваний матеріал ендометріальних аденокарцином, щоб визначити можливу кореляцію між статусом плоїдності та їхніми гістологічними характеристиками. Проводили аналіз свіжих зразків тканин, отриманих резекцією під час повної гістеректомії у пацієнток (n=126). Ми виявили, що статус плоїдності, виявлений за допомогою цитометрії з візуалізацією, корелював із гістологічним типом, ступенем та етапом раку ендометрію, а зразки пухлин із анеуплоїдними клітинами пов’язані зі статистикою агресивного фенотипу. Плоїдність ДНК потрібно використовувати як надійний та застосовний прогностичний маркер у звичайній клінічній практиці.
Ключові слова: плоїдність ДНК, цитометрія з візуалізацією, диплоїд, анеуплоїдія, карцинома ендометрію
Повний текст та додаткові матеріали
Цитована література
Baak, J.P., Snijders, W., van Diermen, B., van Diest, P.J., Diepenhorst, F.W., and Benraadt, J., Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage and 2 endometrial carcinoma, J. Clin. Oncol., 2003, vol. 21, no. 22, pp. 4214–4221. https://doi.org/10.1200/JCO.2003.02.087
Bishop, R., Applications of fluorescence in situ hybridization (FISH) in detecting genetic aberrations of medical significance, Biosci. Horizons, 2010, vol. 3, no. 1, pp. 85–95. https://doi.org/10.1093/biohorizons/hzq009
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA—Cancer J. Clin., 2018, vol. 68, no. 6, pp. 394–424. https://doi.org/10.3322/caac.21492
Danielsen, H.E., Pradhan, M., and Novelli, M., Revisiting tumour aneuploidy—the place of ploidy assessment in the molecular era, Nat. Rev. Clin. Oncol., 2016, vol. 13, no. 5, pp. 291–304. https://doi.org/10.1038/nrclinonc.2015.208
Davoli, T., and de Lange, T., The causes and consequences of polyploidy in normal development and cancer, Annu. Rev. Cell Dev. Biol., 2011, vol. 27, pp. 585–610. https://doi.org/10.1146/annurev-cellbio-092910-154234
Haroske, G., Giroud, F., Reith, A., and Böcking, A., 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology, Anal. Cell. Pathol., 1998, vol. 17, no. 4, pp. 189–200. https://doi.org/10.1155/1998/390837
Hecht, J.L., Ince, T.A., Baak, J.P., Baker, H.E., Ogden, M.W., and Mutter, G.L., Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis, Mod. Pathol., 2005, vol. 18, no. 3, pp. 324–330. https://doi.org/10.1038/modpathol.3800328
Kildal, W., Micci, F., Risberg, B., Abeler, V.M., Kristensen, G.B., Heim, S., and Danielsen, H.E., Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization, Mol. Oncol., 2012, vol. 6, no. 1, pp. 98–107. https://doi.org/10.1016/j.molonc.2011.10.002
Korabiowska, M., Ruschenburg, I., Schlott, T., Kubitz, A., Brinck, U., and Droese, M., Relation between DNA ploidy status and the expression of the DNA-mismatch repair genes MLH1 and MSH2 in cytological specimens of melanoma lymph node and liver metastases, Diagn. Cytopathol., 2001, vol. 24, no. 3, pp. 157–162. https://doi.org/10.1002/1097-0339(200103)24:3<157::aid- dc1033>3.0.co;2-a
Koskas, M., Amant, F., Mirza, M.R., and Creutz-berg, C.L., Cancer of the corpus uteri: 2021 update, Int. J. Gynaecol. Obstet., 2021, vol. 155, Suppl. 1, pp. 45–60. https://doi.org/10.1002/ijgo.13866
Kurman, R.J., Blaustein’s Pathology of the Female Genital Tract, New York: Springer, 2011.
Lax, S.F., Pizer, E.S., Ronnett, B.M., and Kurman, R.J., Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation, Hum. Pathol., 1998, vol. 29, no. 9, pp. 924–931. https://doi.org/10.1016/s0046-8177(98)90197-6
Lax, S.F., Pizer, E.S., Ronnett, B.M., and Kurman, R.J., Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression, Hum. Pathol., 1998, vol. 29, no. 6, pp. 551–558. https://doi.org/10.1016/s0046-8177(98)80002-6
Liu, F.S., Molecular carcinogenesis of endometrial cancer, Taiwan J. Obstet. Gynecol., 2007, vol. 46, no 1, pp. 26–32. https://doi.org/10.1016/S1028-4559(08)60102-3
Lundgren, C., Auer, G., Frankendal, B., Moberger, B., Nilsson, B., and Nordström, B., Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma, Int. J. Gynecol. Cancer, 2002, vol. 12, no. 1, pp. 110–118. https://doi.org/10.1046/j.1525-1438.2002.01079.x
Mauland, K.K., Wik, E., and Salvesen, H.B., Clinical value of DNA content assessment in endometrial cancer, Cytometry, Part B, 2014, vol. 86, no. 3, pp. 154–163. https://doi.org/10.1002/cyto.b.21164
Mauland, K.K., Wik, E., Hoivik, E.A., Kusonmano, K., Halle, M.K., Berg, A., Haugland, H.K., Øyan, A.M., Kalland, K.H., Stefansson, I.M., Akslen, L.A., Krakstad, C., Trovik, .J, Werner, H.M., and Salvesen, H.B., Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival, Oncotarget, 2017, vol. 8, no. 6, pp. 9696–9707. https://doi.org/10.18632/oncotarget.14201
Mutter, G.L., Baak, J.P., Crum, C.P., Richart, R.M., Ferenczy, A., and Faquin, W.C., Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry, J. Pathol., 2000, vol. 190, no. 4, pp. 462–469. https://doi.org/10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D
Nordström, B., Strang, P., Lindgren, A., Bergström, R., and Tribukait, B., Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications?, Int. J. Gynecol. Pathol., 1996, vol. 15, no. 3, pp. 191–201. https://doi.org/10.1097/00004347-199607000-00002
Oehler, M.K., Brand, A, and Wain, G.V., Molecular genetics and endometrial cancer, J. Br. Menopause Soc., 2003, vol. 9, no. 1, pp. 27–31. https://doi.org/10.1258/136218003100322116
Origoni, M., De Marzi, P., Almirante, G., Ottolina, J., Frigerio, L., Carnelli, M., Gelardi C., and Candiani, M., The prognostic value of DNA ploidy determination in endometrial cancer, J. Clin. Exp. Oncol., 2013, vol. 2, no. 1. https://doi.org/10.4172/2324-9110.1000105
Pradhan, M., Abeler, V.M., Danielsen, H.E., Tropé, C.G., and Risberg, B.A., Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas, Mod. Pathol., 2006, vol. 19, no. 9, pp. 1227–1235. https://doi.org/10.1038/modpathol.3800641
Pradhan, M., Abeler, V.M., Danielsen, H.E., Sandstad, B., Tropé, C.G., Kristensen, G.B., and Risberg, B.Å., Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium, Ann. Oncol., 2012, vol. 23, no. 5, pp. 1178–1184. https://doi.org/10.1093/annonc/mdr368
Prat, J., Prognostic parameters of endometrial carcinoma, Hum. Pathol., 2004, vol. 35, no. 6, pp. 649-662. https://doi.org/10.1016/j.humpath.2004.02.007
Salvesen, H.B., and Akslen, L.A., Molecular pathogenesis and prognostic factors in endometrial carcinoma, AP-MIS, 2002, vol. 110, no. 10, pp. 673–689. https://doi.org/10.1034/j.1600-0463.2002.1101001.x
Sasaki, K., Kurose, A., Miura, Y., Sato, T., and Ikeda, E., DNA ploidy analysis by laser scanning cytometry (LSC) in colorectal cancers and comparison with flow cytometry, Cytometry, 1996, vol. 23, no. 2, pp. 106–109. https://doi.org/10.1002/(SICI)1097-0320(19960201)23:2<106::AID-CYTO3>3.0.CO;2-I
Susini, T., Amunni, G., Molino, C., Carriero, C., Rapi, S., Branconi, F., Marchionni, M., Taddei, G., and Scarselli, G., Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: DNA aneuploidy identifies high-risk cases among the so-called ‘low-risk’ patients with well and moderately differentiated tumors, Cancer, 2007, vol. 109, no. 5, pp. 882–890. https://doi.org/10.1002/cncr.22465
Terada, K., DNA ploidy in endometrial cancer: unfinished business?, Ann. Oncol., 2012, vol. 23, no. 5, pp. 1083–1084. https://doi.org/10.1093/annonc/mdr549
Uharcek, P., Prognostic factors in endometrial carcinoma, J. Obstet. Gynaecol. Res., 2008, vol. 34, no. 5, pp. 776−783. https://doi.org/10.1111/j.1447-0756.2008.00796.x
WHO Classification of Tumours Editorial Board, Female Genital Tumours, Lyon: IARC, 2020.
Wik, E., Trovik, J., Iversen, O.E., Engelsen, I.B., Stefansson, I.M., Vestrheim, L.C., Haugland, H.K., Akslen, L.A., and Salvesen, H.B., Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting, Am. J. Obstet. Gynecol., 2009, vol. 201, no. 6, p. 603.e1-7. https://doi.org/10.1016/j.ajog.2009.07.029
Wimberger, P., Hillemanns, P., Kapsner, T., Hepp, H., and Kimmig, R., Evaluation of prognostic factors following flow-cytometric DNA analysis after cytokeratin labelling: II. Cervical and endometrial cancer, Anal. Cell. Pathol., 2002, vol. 24, nos. 4–5, pp. 147–158. https://doi.org/10.1155/2002/346969
Zaino, R.J., Davis, A.T., Ohlsson-Wilhelm, B.M., and Brunetto, V.L., DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study, Int. J. Gynecol. Pathol., 1998, vol. 17, no. 4, pp. 312–319. https://doi.org/10.1097/00004347-199810000-00004